NovaBridge Biosciences American Depositary SharesNBP

NovaBridge is a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets, enabling transformative therapies to progress rapidly from discovery toward patients in need. The Company's differentiated pipeline is led by givastomig, a potential first-in-class Claudin 18.2-Targeted Immuno Amplifier (CTIA) - a Claudin 18.2 * 4-1BB bispecific antibody - and VIS-101, a purpose-designed, potential best-in-class dual VEGF-A * ANG-2.

novabridge.com